Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Activation and Inhibition of Human HSCs and the Related Molecular Mechanisms

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Clearance of Activated Stellate Cells for Hepatic Fibrosis Regression: Molecular Basis and Translational Potential

Study progress of the molecular mechanisms and therapies of liver fibrosis

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Modulation of hepatic stellate cells and reversibility of hepatic fibrosis.

Mechanisms of hepatic stellate cell activation

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

Cellular Mechanisms in Liver Fibrosis Regression

Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

In Situ Regulation and Mechanisms of 3D Matrix Stiffness on the Activation and Reversion of Hepatic Stellate Cells.

Liver Fibrosis: the Status Quo and the Prospect

Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis

New insights into fibrotic signaling in hepatocellular carcinoma

The Progression for the Therapy of Liver Fibrosis Targeting to Hepatic Stellate Cells

Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis